BioPharm International, October 2010 - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

BioPharm International, October 2010
Features
Biopharmacetiucal Approval Trends in 2009
By Gary Walsh, PhD
Biotech approvals were up last year. Is it a sign of a new trend?
The Role of Noncritical Process Parameters in Quality by Design
By Laura Bush
Industry and regulators disagree over noncritical parameters.
Regulatory Beat
Biotech Companies Gain Support for Vaccine, Countermeasure Production
By Jill Wechsler
A new strategy to streamline vaccine development and oversight.
Outsourcing Insights
Uncertain Outlook for Biopharma Venture Capital
By Jim Miller
Venture capital is still scarce for early biotechs and their providers.
Downstream Trends
Regulatory Challenges Impede the Adoption of New Downstream Processing Technologies
By Eric S. Langer
Can vendor—user partnerships overcome the typical wait-and-see attitude toward new technologies?
Burrill on Biotech
Biotech Cools Off as Capital Markets Weaken
By G. Steven Burrill
Biotech's mid-sized elites position themselves for growth.
From the Editor
Taking on the Challenges
By Laura Bush
Good leaders look beyond industry woes to focus on patients
Final Word
A Quality Culture Can Be the Industry's Core Strength
By Mary Oates
How should the industry educate the public about product quality?

ADVERTISEMENT

ADVERTISEMENT

Click here